cyrilzakka/clinical-trials huggingface dataset:
Relation Between Vasovagal Tendency and Smoking Among University Students

Almost everyone is aware these days is aware about the risk of smoking. Still many people start this habit specially in early life and during college year. We aim to investigate in this study if there is a drive to smoke in people with vasovagal tendency to improve their symptoms, even if not aware of this. Vasovoagal symptoms are common and include dizziness, smoking, sweating, abdominal pain, fatigue and syncope. Some studies have shown correlation between smoking and a positive tilt table test which is indicative of vasovagal tendency. By collecting the information regarding smoking habit and vasovagal symptoms analysis can be done to see if there is correlation between these two factors

Methods

A questionnaire will be conducted among university students to investigate the tendency toward vasovagal symptoms and also smoking habits. Statistical correlation will be subsequently conducted to see if there is correlation between those two problems (vasovagal symptoms and smoking)

Study criteria inclusion

Benefit to the patient:

There is no direct benefit for participation in the study. The information obtained may help in the future to find factors that increase smoking and being aware of these factors may help in controlling the habit of smoking.

Eligibility Criteria:
Inclusion Criteria:

* College students who agree to participate in the questionnaire

Exclusion Criteria:

* Unable or does not consent to fill the form
Clinical Performance of Dual- and Light-cure Bulk-fill Resin Composites

This study (a double-blinded, prospective, randomized clinical trial) aimed to evaluate 2-year clinical performance of dual- and light-cure bulk-fill resin composites in Class ӀӀ restorations.

The null hypothesis tested in this study was that, there would be no difference in the 2-year clinical performance of all tested bulk-fill resin composites in Class II restorations.

Forty patients were enrolled in the study. Each patient received three bulk-fill resin composites Class ӀӀ restorations. One dual-cure and two light-cure bulk-fill resin composites were used for Class ӀӀ restorations following manufacturer's instructions. A universal adhesive was used with all restorations. All restorations were clinically evaluated after 1 week (baseline), 6 months, 12 months, 18 months and finally after 24 months using the FDI World Dental Federation criteria.


Eligibility Criteria:
Inclusion Criteria:

* each participant should have at least three permanent molars and premolars that need to be treated with Class II restorations due to primary carious lesions.
* all participants required to have a full and normal occlusion and to maintain adequate oral hygiene.

Exclusion Criteria:

General exclusion criteria:

* heavy bruxism.
* poor oral hygiene.
* chronic or severe periodontitis.
* a history of allergies to any of the materials utilized in this study.
* pregnant or nursing females.

Specific exclusion criteria:

* fractured or visibly cracked teeth.
* rampant caries.
* faulty restoration opposite or adjacent to the tooth to be restored.
* atypical extrinsic staining.
The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus

This study aims at investigating the effect of hyperglycaemia on physical performance and local energy stores in the muscle in patients with type 1 diabetes mellitus under exercise conditions.


Eligibility Criteria:
Inclusion Criteria:

* Male
* Aged from 20 to 40 years
* Patients with type 1 diabetes mellitus lasting for at least 5 years (C-Peptide ≤ 0.3 nmol/l in the presence of a plasma glucose level ≥ 7 mmol/L, indicating insulin dependence)
* Insulin delivery by CSII (continuous subcutaneous insulin infusion) for at least 6 months
* Acceptable to good metabolic control, reflected by an HbA1c 5-8%
* Normal insulin sensitivity, reflected by a daily insulin requirement of 0.3-1.0 U/kg body weight
* minimum 30' of moderate exercise 3 times per week
* BMI in the range of 18-25 kg/m2

Exclusion Criteria:

* Chronic complications of diabetes:

  * Microalbuminuria (Mogensen nephropathy stadium ≥ III)
  * Sensory neuropathy (vibration better than 5/8 at the metatarsophalangeal articulation of digitus I)
  * Proliferating retinopathy
  * No history of macro-vascular complications
  * Clinically relevant autonomous neuropathy
* Smoking
* Abnormal thyroid function
* Major depression, psychosis and other severe personality disorders, claustrophobia
* Active neoplasia
* Contraindications to exposure to a 1.5 T magnetic field (pace-makers, osteosynthetic material, etc.)
* Abnormal liver or renal function (creatinine \> 130 µmol/L; ASAT and ALAT \> 3 times the upper reference limit)
* Excessive alcohol consumption (\>60g/d) or drug-abuse
* Refusal to give written informed consent
* Participation in another study
* Patients, who are not suitable for the study according to the study physician
Feasibility of Doppler Ultrasound for Pulse Detection in Out-of-Hospital Cardiac Arrest Patients

The goal of this prospective observational study is to investigate the feasibility of using doppler point-of-care ultrasound on the femoral artery with a portable device to assess the presence of a pulse in patients suffering from cardiac arrest in the out-of-hospital environment. The main question is how often researchers are successful in acquiring the necessary ultrasound signal in the out-of-hospital environment.

In this prospective observational study, a dedicated research team will be dispatched to cardiac arrest patients treated in the prehospital environment by emergency medical services (EMS). The team will use a portable ultrasound device to identify the femoral artery and conduct a pulsed wave (PW) doppler measurement during chest compressions as well as during chest compression pauses for rhythm analysis and save the recorded images. These ultrasound pulse checks will be conducted in parallel with the normal treatment of the patient, including manual pulse checks, and will only be conducted if ultrasound is possible without interference in the resuscitation. All treatment decisions will rest with the treating EMS team.

Eligibility Criteria:
Inclusion Criteria:

* Out-of-hospital cardiac arrest treated by EMS
* Minimum age of 18 years

Exclusion Criteria:

* Pregnancy or suspected pregnancy
* Disapproval of the treating EMS team
* Adults under legal guardianship
* Inability to perform femoral artery doppler ultrasound due to limited access to the patient and possible interference with the treating EMS team
* Inability to perform femoral artery doppler ultrasound due to injuries or anatomic abnormalities in the femoral region or necessary emergent medical interventions in the femoral region
* Decision to transfer the patient to the hospital with ongoing CPR for emergent procedures such as extracorporeal CPR before femoral artery doppler ultrasound could be attempted
* Inability to safely perform femoral artery doppler ultrasound due to environmental hazards
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present in your body. TVI-Brain-1 is designed to generate large numbers of those 'killer' white blood cells and to deliver those cells into your body so that they can kill your cancer cells.

The TVI-Brain-1 treatment involves several steps. First, the patient's cancer will be surgically removed to provide cells for the vaccine. Second, the patient will be vaccinated with the vaccine formulation. Third, the patient's blood will be filtered for killer T cell precursors which will then be cultured and stimulated to reach a higher (killer) activity level. Fourth, the activated cells will be infused into the patient's bloodstream so that they will be able to attack the cancer.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18
* Informed consent
* Diagnosis of grade IV glioma with progression following standard treatment.
* Must be able to tolerate surgery to provide tumor tissue for vaccine.
* Must be able to produce viable vaccine from tumor tissue.
* Karnofsky Performance Status must be 70 or greater.
* Negative HIV test.
* Negative for hepatitis B and C virus.
* Respiratory reserve must be reasonable.
* Sufficient renal function.
* Satisfactory blood counts.
* Negative pregnancy test for women of childbearing potential.

Exclusion Criteria:

* Surgically removed cancer reveals that it is not grade IV glioma.
* Concomitant life-threatening disease.
* Active autoimmune disease.
* Currently receiving chemotherapy or biological therapy for the treatment of cancer.
* Currently receiving immunosuppressive drugs for any reason.
* Prior treatment with Avastin or other anti-angiogenesis treatment within 6 months.
* Prior treatment with Gliadel wafers.
* Corticosteroids beyond peri-operative period.
* Psychological, familial, sociological or geographical conditions that do not permit adequate medical follow-up and compliance with the study protocol.
Host Genetic Susceptibility to Avian Influenza A/H5N1

The identification and characterization of susceptibility loci for H5N1 infection in humans could have profound implications. The detection of host genetic factors may shed light on key pathogenic interactions between H5N1 and human cells, assisting in identifying the viral characteristics determining pandemic potential. In addition, the identification and verification of susceptibility loci would be followed by functional studies which might point the way to new therapeutic and preventive options.

The objective of this study is to investigate if host genetic factors are associated with susceptibility to influenza H5N1 illness

This is primarily an hypothesis screening exercise and while guesses based on biological plausibility are possible, a comprehensive analysis of genetic susceptibility can only be achieved by a whole genome approach. Therefore we will test for genetic linkage and association using a large number of Single Nucleotide Polymorphisms (SNPs) spanning the whole genome.

Principal Investigators have access to information on all surviving and deceased laboratory confirmed H5N1 cases. These cases will form the study base. The epidemiologist will attempt to make telephone contact with either the recovered patient or,if the patient died, the closest relative of the deceased patient. The proposed study will be explained and permission will be sought for the epidemiologist and a study nurse to visit the household to explain the study in greater detail, to offer an opportunity for questions and, if the subject agrees, to obtain informed consent for participation. If the epidemiologist has difficulty in making contact with the case or their family the local public authorities will be asked to assist in making contact. Eligible family members of H5N1 cases will be identified by face-to-face interviews with the surviving confirmed cases or close family members of deceased cases.

Eligibility Criteria:
Inclusion Criteria:

* The individual had a clinically compatible illness (defined as respiratory symptoms and an abnormal chest x-ray or encephalitis), AND
* Influenza A/H5 RNA identified in a clinical sample by reverse transcription-polymerase chain reaction \[RT-PCR\], OR
* Influenza A/H5 cultured from a clinical sample, OR
* High titres (1:80 or higher) of anti-H5 antibodies by microneutralization in convalescent samples of patients who had a compatible illness but no or negative RT-PCR, AND
* The patient survived or if they died an archived biological specimen is available for potential DNA extraction, AND
* Valid, written consent is obtained.
* The biological parents and biological siblings of all the cases and any other family members linking two cases, AND
* Valid, written consent is obtained.
Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19

This study will compare the impact of two systems above low-flow nasal cannula on the arterial oxygen tension in patients with COVID-19. The two systems are the Surgical Mask (SM) and the Double-Trunk Mask (DTM).

Hospitalized patients with COVID-19 typically present with hypoxemia. In some patients, hypoxemia can be corrected with low flow nasal cannula. When placed above nasal cannula, some systems have demonstrated their interest in improving the performance of patient's oxygen delivery. For example, two recent studies have shown that adding a Double-Trunk Mask (DTM) or Surgical Mask (SM) above nasal cannula has the potential to improve the PaO2 despite no change in oxygen output (Duprez et al., J Clin Monit Comput 2020; Montiel et al., Ann Intensive Care 2020). However, there is no study comparing the relative effectiveness of these 2 systems.

Eligibility Criteria:
Inclusion Criteria:

* COVID-19 positive
* SpO2 between 92 and 96% with low-flow oxygen therapy
* Oxygen output at baseline between 3 and 7 L/min.

Exclusion Criteria:

* Pulmonary disease with hypercapnia
* Confusion
* Contra-indications to arterial blood gas sampling (peripheral arteriopathy, bleeding disorder)
Preoperative Ultrasound-Guided Peri- Capsular Nerve Group Block on Postoperative Analgesia After Shoulder Arthroscopic Surgery

This study aimed to evaluate the analgesic efficacy of preoperative ultrasound-guided peri-capsular nerve group block (PENG) on postoperative analgesia after shoulder arthroscopic surgery.

Postoperative pain control after shoulder surgery is challenging, and poor pain management is invariably reflected in poor outcomes, with longer hospitalization and recovery time. The difﬁculty in reducing pain due to the complexity of shoulder innervation leads to conducting studies to explore selective axillary nerve blocks with a posterior approach or from the axillae.

The peri-capsular nerve group (PENG) block is a regional anesthetic technique. It can be effectively and safely applied under ultrasound guidance in shoulder surgery cases for postoperative analgesia. It targets only the sensory branches and not the posterior mechanoreceptors; there is a potential motor-sparing effect which is desirable for better physical therapy, and earlier discharge.

Eligibility Criteria:
Inclusion Criteria:

* Age from 21 to 65 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status I-III.
* Scheduled for unilateral shoulder arthroscopic surgery.

Exclusion Criteria:

* Patient refusal.
* Known hypersensitivity to local anesthetics.
* Body mass index\> 35 kg /m2.
* Uncooperative or psychiatric patients.
* Infection at the injection site.
* Coagulation disorder.
* Major cardiac, renal, or hepatic diseases.
Scheduled Elective Surgical Case Cancellation in Siriraj: Evaluation and Identification of the Reasons

A retrospective cross-sectional analytic study to evaluation and identification of the reasons about Scheduled elective surgical case cancellation in Siriraj Hospital, reason of cancellation will be extracted from hospital medical record of each case, reviewed and divided into 2 groups, with SiPAC and without SiPAC consultation. Primary outcomes are the incidence of cancelled case and causes of the cancellation and secondary outcome that will be identified for areas of improvement.

After approval by the Siriraj Institutional Review Board. All data of case cancellation on scheduled elective surgical procedures will be retrieved from database of the department of Anesthesiology, Faculty of Medicine Siriraj Hospital. Then, reason of cancellation will be extracted from hospital medical record of each case. All cases will be checked in database of SiPAC, department of Anesthesiology, Faculty of Medicine Siriraj Hospital to confirm whether each patient was preoperatively consulted. All patients having cancellation on scheduled elective surgery in the period of one year will be reviewed. Exclusion criteria is 1) patients having emergency or urgency surgery which means patients' names were not appeared in the surgical schedules 2) having missing key medical information.

Admission records and patient charts will be reviewed and divided into 2 groups, with SiPAC and without SiPAC consultation. Primary outcomes are the incidence of cancelled case and causes of the cancellation which will be recorded and categorized into 6 groups including 1) patient issue such as surgery refusal, no show on the day of surgery, transport problems 2) facility such as equipment needs, improper estimate case time, case bumps 3) Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively 4) anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error 5) medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure 6) miscellaneous. The results compared between in patients with and without SiPAC consultation will be analyzed as a secondary outcome that will be identified for areas of improvement.

Eligibility Criteria:
Inclusion Criteria:

* all data of case cancellation on scheduled elective surgical procedures

Exclusion Criteria:

* patients having emergency or urgency surgery which means patients' names were not appeared in the surgical schedules
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France

The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of oral azacitidine prescribed as maintenance treatment after frontline treatment or second remission for acute myeloid leukemia in France.


Eligibility Criteria:
Inclusion Criteria:

* Participants who initiated oral azacitidine maintenance therapy during early access program (EAP) in France (January 29, 2021 to July 13, 2022) or during the 6 months post-EAP (from July 14, 2022, to January 2014, 2023) inside the marketing authorization label "adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT)."
* Participants with histologically confirmed diagnosis of de novo AML, or therapy-related AML, or secondary AML
* Participants who received frontline treatment after diagnosis of AML and achieved complete remission (CR), CR with incomplete blood count recovery (Cri), or CR with partial hematology recovery (CRh) after one or subsequent lines of therapy in case of relapse
* Participant is at least 18 years of age at the time of initial diagnosis of AML
* Participants alive or deceased at the time of data collection
* Physician has access to the complete medical record for the patient, including any transferred records from other facilities (if applicable); patient's medical record must at least include the following:

  * Date of diagnosis of AML
  * Frontline therapy(ies) received, and treatment start dates
  * Date(s) of first documented evidence of response
  * Oral azacitidine start and (if applicable) stop date
  * Documentation (yes/no) of relapse on oral azacitidine, where applicable
* Participants who do not object to the data collection

Exclusion Criteria:

* Participants who initiated maintenance with oral azacitidine after January 14, 2023
* Participant who initiated maintenance with oral azacitidine before January 14, 2023, outside of the marketing authorization label
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9

This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.

The purpose of this study is to evaluate expression of vascular adhesion protein 1 (VAP-1) in bone marrow and cancerous lesions before and after therapy using 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT). Patients with acute myeloid leukemia (AML) that undergo bone marrow transplantation and patients with melanoma and lung cancer that undergo chemotherapy will be studied. In addition, imaging results will be compared with clinical data and research data from blood samples. The study is of great clinical importance as other methods do not provide such comprehensive information on the presence of the VAP-1 molecule in the body, especially in the bone marrow and cancer tissue before and after cancer treatment. Research is also important for drug development targeting VAP-1.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures.
* Diagnosis of metastatic melanoma and fit for immune checkpoint inhibitors or BRAF- and MEK inhibitors.
* Diagnosis of metastatic non-small cell lung cancer (NSCLC) (stage IV) and fit for immune checkpoint inhibitors and/or chemotherapy.
* Able and willing to give written informed consent and to comply with the study protocol.

Exclusion Criteria:

* Unsuitable for alloHSCT (AML), checkpoint inhibitors or BRAF- and MEK inhibitors (melanoma or checkpoint inhibitors and/or chemotherapy (NSCLC) according to the standard operating procedures.
* Unable or unwilling to comply with the study protocol for any reason.
* Evidence of significant uncontrolled concomitant diseases such as neurological, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the Investigator, would preclude patient participation